Vimseltinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Vimseltinib. Educational only — not medical advice.
Labeled uses
ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Source: FDA labeling via NIH DailyMed (set f73c7a62…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.